BR112014000341A2 - proteína de ligação ao antígeno, método para tratamento de um paciente com uma doença, uso de uma proteína de ligação ao antígeno, ácido nucleico, e, célula hospedeira - Google Patents
proteína de ligação ao antígeno, método para tratamento de um paciente com uma doença, uso de uma proteína de ligação ao antígeno, ácido nucleico, e, célula hospedeiraInfo
- Publication number
- BR112014000341A2 BR112014000341A2 BR112014000341A BR112014000341A BR112014000341A2 BR 112014000341 A2 BR112014000341 A2 BR 112014000341A2 BR 112014000341 A BR112014000341 A BR 112014000341A BR 112014000341 A BR112014000341 A BR 112014000341A BR 112014000341 A2 BR112014000341 A2 BR 112014000341A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen binding
- binding protein
- disease
- patient
- treating
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title 2
- 108091000831 antigen binding proteins Proteins 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1112429.4A GB201112429D0 (en) | 2011-07-19 | 2011-07-19 | Antigen-binding proteins with increased FcRn binding |
PCT/EP2012/064129 WO2013011076A2 (en) | 2011-07-19 | 2012-07-19 | Antigen-binding proteins with increased fcrn binding |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014000341A2 true BR112014000341A2 (pt) | 2017-02-14 |
Family
ID=44586854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014000341A BR112014000341A2 (pt) | 2011-07-19 | 2012-07-19 | proteína de ligação ao antígeno, método para tratamento de um paciente com uma doença, uso de uma proteína de ligação ao antígeno, ácido nucleico, e, célula hospedeira |
Country Status (21)
Country | Link |
---|---|
US (1) | US20130243764A1 (pt) |
EP (2) | EP3009450A1 (pt) |
JP (1) | JP2014524748A (pt) |
KR (1) | KR20140054085A (pt) |
CN (1) | CN103748110A (pt) |
AU (1) | AU2012285786B2 (pt) |
BR (1) | BR112014000341A2 (pt) |
CA (1) | CA2841105A1 (pt) |
CL (1) | CL2014000134A1 (pt) |
CO (1) | CO6862106A2 (pt) |
CR (1) | CR20140029A (pt) |
DO (1) | DOP2014000007A (pt) |
EA (1) | EA201391789A1 (pt) |
ES (1) | ES2600854T3 (pt) |
GB (1) | GB201112429D0 (pt) |
MA (1) | MA35345B1 (pt) |
MX (1) | MX2014000739A (pt) |
PE (1) | PE20141660A1 (pt) |
SG (1) | SG10201601154QA (pt) |
WO (1) | WO2013011076A2 (pt) |
ZA (1) | ZA201400062B (pt) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140186361A1 (en) | 2012-09-07 | 2014-07-03 | Coherus Biosciences, Inc. | Stable Aqueous Formulations of Adalimumab |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
MX363700B (es) | 2012-03-07 | 2019-03-29 | Cadila Healthcare Ltd | Formulaciones farmaceuticas de anticuerpos tnf-alfa. |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158275A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
JP2015519382A (ja) * | 2012-06-12 | 2015-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療用抗体のための医薬処方物 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
FR2999431B1 (fr) * | 2012-12-17 | 2016-03-18 | Lfb Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
EP3514175A1 (fr) * | 2012-12-17 | 2019-07-24 | Laboratoire Français du Fractionnement et des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
BR112015017619A2 (pt) * | 2013-01-24 | 2017-11-21 | Glaxosmithkline Ip Dev Ltd | formulação líquida, uso de uma formulação, e, kit |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
BR112015017307A2 (pt) * | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
CN105377237B (zh) * | 2013-07-19 | 2019-04-19 | 德国赫素制药集团 | 使免疫反应的调节与生物药品的给药相关的方法和制剂 |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
JP6526025B2 (ja) * | 2013-10-16 | 2019-06-05 | オンコバイオロジクス,インコーポレイティド | 抗体安定性を増強する緩衝液製剤 |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
PT2946765T (pt) | 2014-05-23 | 2016-11-10 | Ares Trading Sa | Composição farmacêutica líquida |
ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
UY36542A (es) * | 2015-01-28 | 2016-08-31 | Mabxience S A | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa |
WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
JP6954842B2 (ja) * | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
AU2017213775A1 (en) | 2016-02-03 | 2018-08-16 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
JP7155008B2 (ja) | 2016-03-14 | 2022-10-18 | ウニヴァーシテテット イ オスロ | 変化されたFcRnを有する改変された免疫グロブリン |
WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
BR112019001989A2 (pt) | 2016-08-02 | 2019-08-20 | Visterra Inc | polipeptídeos projetados e usos dos mesmos |
US11286295B2 (en) * | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
AU2018207367B2 (en) * | 2017-01-11 | 2024-02-15 | Celltrion Inc. | Stable Liquid Formula |
WO2018129713A1 (zh) * | 2017-01-13 | 2018-07-19 | 杭州翰思生物医药有限公司 | 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法 |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372241A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
CA3072099A1 (en) * | 2017-08-11 | 2019-02-14 | Research Development Foundation | Engineered antibody fc variants for enhanced serum half life |
KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
EP3743441A1 (en) * | 2018-01-26 | 2020-12-02 | Genzyme Corporation | Fc variants with enhanced binding to fcrn and prolonged half-life |
KR20210137499A (ko) * | 2019-03-05 | 2021-11-17 | 더 스테이트 오브 이스라엘, 미니스트리 오브 애그리컬처 & 루럴 디벨로프먼트, 애그리컬처럴 리서치 오거니제이션, (에이.알.오.), 볼카니 센터 | 게놈-편집 조류 |
WO2023098694A1 (zh) * | 2021-11-30 | 2023-06-08 | 江苏恒瑞医药股份有限公司 | 一种抗sost抗体药物组合物及其用途 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
DK0929578T3 (da) * | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
SI1562972T1 (sl) | 2002-10-15 | 2010-12-31 | Facet Biotech Corp | ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO |
US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
EP2684895A1 (en) * | 2006-10-27 | 2014-01-15 | AbbVie Biotechnology Ltd | Crystalline anti-hTNFalpha antibodies |
DK3216802T3 (da) | 2007-08-20 | 2021-01-04 | Glaxo Group Ltd | Produktionsfremgangsmåde |
CL2008003561A1 (es) * | 2007-11-30 | 2010-02-05 | Glaxo Group Ltd | Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias. |
NZ602498A (en) * | 2007-11-30 | 2014-08-29 | Abbvie Inc | Protein formulations and methods of making same |
WO2009073805A2 (en) * | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
SI2235059T1 (sl) * | 2007-12-26 | 2015-06-30 | Xencor, Inc. | Fc variante s spremenjeno vezjo na fcrn |
EP2225276B1 (en) * | 2007-12-31 | 2014-04-23 | Bayer Intellectual Property GmbH | Antibodies to tnf alpha |
FR2934599B1 (fr) | 2008-07-29 | 2012-12-21 | Arkema France | Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations |
US9393304B2 (en) * | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
CA2753287A1 (en) * | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
EP2403531A4 (en) * | 2009-03-05 | 2013-02-27 | Abbott Lab | IL-17 BINDING PROTEINS |
NZ595694A (en) * | 2009-05-04 | 2013-09-27 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
CN102458471A (zh) * | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合 |
WO2011074965A1 (en) * | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
TWI603739B (zh) | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
-
2011
- 2011-07-19 GB GBGB1112429.4A patent/GB201112429D0/en not_active Ceased
-
2012
- 2012-07-19 EA EA201391789A patent/EA201391789A1/ru unknown
- 2012-07-19 KR KR1020147004161A patent/KR20140054085A/ko not_active Application Discontinuation
- 2012-07-19 BR BR112014000341A patent/BR112014000341A2/pt not_active IP Right Cessation
- 2012-07-19 WO PCT/EP2012/064129 patent/WO2013011076A2/en active Application Filing
- 2012-07-19 PE PE2014000086A patent/PE20141660A1/es not_active Application Discontinuation
- 2012-07-19 ES ES12738101.0T patent/ES2600854T3/es active Active
- 2012-07-19 AU AU2012285786A patent/AU2012285786B2/en not_active Ceased
- 2012-07-19 US US13/988,400 patent/US20130243764A1/en not_active Abandoned
- 2012-07-19 MX MX2014000739A patent/MX2014000739A/es unknown
- 2012-07-19 SG SG10201601154QA patent/SG10201601154QA/en unknown
- 2012-07-19 EP EP15197750.1A patent/EP3009450A1/en not_active Withdrawn
- 2012-07-19 JP JP2014520658A patent/JP2014524748A/ja active Pending
- 2012-07-19 CA CA2841105A patent/CA2841105A1/en not_active Abandoned
- 2012-07-19 EP EP12738101.0A patent/EP2734548B1/en active Active
- 2012-07-19 CN CN201280034887.5A patent/CN103748110A/zh active Pending
-
2014
- 2014-01-06 ZA ZA2014/00062A patent/ZA201400062B/en unknown
- 2014-01-17 DO DO2014000007A patent/DOP2014000007A/es unknown
- 2014-01-17 CL CL2014000134A patent/CL2014000134A1/es unknown
- 2014-01-20 CR CR20140029A patent/CR20140029A/es unknown
- 2014-01-21 CO CO14011137A patent/CO6862106A2/es not_active Application Discontinuation
- 2014-02-12 MA MA36748A patent/MA35345B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CL2014000134A1 (es) | 2014-07-25 |
CO6862106A2 (es) | 2014-02-10 |
SG10201601154QA (en) | 2016-03-30 |
CN103748110A (zh) | 2014-04-23 |
ZA201400062B (en) | 2017-08-30 |
GB201112429D0 (en) | 2011-08-31 |
AU2012285786A1 (en) | 2014-02-06 |
EP2734548B1 (en) | 2016-08-17 |
PE20141660A1 (es) | 2014-11-21 |
KR20140054085A (ko) | 2014-05-08 |
US20130243764A1 (en) | 2013-09-19 |
AU2012285786B2 (en) | 2016-05-12 |
WO2013011076A2 (en) | 2013-01-24 |
MX2014000739A (es) | 2014-02-19 |
CR20140029A (es) | 2014-03-05 |
EP2734548A2 (en) | 2014-05-28 |
DOP2014000007A (es) | 2014-04-30 |
CA2841105A1 (en) | 2013-01-24 |
JP2014524748A (ja) | 2014-09-25 |
EA201391789A1 (ru) | 2014-06-30 |
NZ618897A (en) | 2016-02-26 |
ES2600854T3 (es) | 2017-02-13 |
MA35345B1 (fr) | 2014-08-01 |
WO2013011076A3 (en) | 2013-04-04 |
EP3009450A1 (en) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014000341A2 (pt) | proteína de ligação ao antígeno, método para tratamento de um paciente com uma doença, uso de uma proteína de ligação ao antígeno, ácido nucleico, e, célula hospedeira | |
BR112014026990A2 (pt) | anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia. | |
BR112015029788A2 (pt) | hetero-multímero, construto de anticorpo isolado, ácido nucleico, célula hospedeira, método para preparar o hetero-multímero, composição farmacêutica, método para tratar uma doença, uso do hetero-multímero, uso de uma quantia terapêutica do hetero-multímero e método para reduzir a função efetora de um construto de anticorpo | |
BRPI1008145A2 (pt) | proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente. | |
BR112012020372A8 (pt) | anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante | |
BR112013020070A2 (pt) | moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas | |
EP3076949A4 (en) | Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis | |
CL2012002416A1 (es) | Proteina de union capaz de unirse a dll4; construccion de anticuerpo que comprende dicha proteina; conjugado de anticuerpo; acido nucleico, vector y celula huesped que comprenden el anticuerpo; composicion para la liberacion de una proteina de union; metodo para reducir la actividad del dll4 humano. | |
BRPI1010109A2 (pt) | proteína de ligação ao antígeno tetravalente e biespecífica, método para a preparação de uma proteína de ligação ao antígeno tetravalente e biespecífica, célula hospedeira, composição farmacêutica, uso da proteína de ligação ao antígeno tetravalente biespecífica e método para o tratamento de um paciente que necessita de terapia | |
BR112014002621A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento | |
BR112015012644A2 (pt) | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; | |
AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
BR112014007789A2 (pt) | sistemas e métodos para análise biológica | |
BR112013024948A2 (pt) | aparelho e método para identificar estados biológicos importante em um animal | |
BR112014027166A2 (pt) | anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção. | |
SG11201403450VA (en) | Artificial nucleic acid molecules for improved protein or peptide expression | |
CL2013003043A1 (es) | Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune. | |
BRPI0911571A2 (pt) | método para tratar um mamífero, análogo de insulina, ácido nucléico e célula hospedeira | |
BR112014010186A2 (pt) | formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal | |
BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
BR112013024574A2 (pt) | polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo | |
AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
BR112013030381A2 (pt) | reagentes e métodos para tratar doença dental | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2471 DE 15-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |